MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats
Yt. Liu et al., MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats, BRAIN RES, 862(1-2), 2000, pp. 111-119
The purpose of this study was to evaluate the effects of MRZ 2/579, an unco
mpetitive N-methyl-D-aspartate antagonist, on infarct size, extent of swell
ing and neurological deficit in a model of transient middle cerebral artery
occlusion in rats. Physiologically controlled Sprague-Dawley rats received
2 h MCAo by retrograde insertion of an intraluminal suture coated with pol
y-L-lysine. The agent (MRZ 2/579) or vehicle (sodium chloride 0.9%) was adm
inistered i.v. immediately after suture removal following a 2-h period of M
CAo. Two experimental groups were studied: group A was treated by vehicle (
bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6
h). Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min fo
llowed by infusion of 6 mg/kg/h over 6 h). The neurological status was eval
uated during occlusion (at 60 min) and daily for 3 days after MCAo. Brains
were then perfusion-fixed, and infarct volumes and brain swelling were dete
rmined. MRZ 2/579 significantly improved the neurological score compared to
vehicle-treated rats at 48 h (6.2+/-0.6 and 8.7+/-0.5, respectively; P<0.0
04) and 72 h after MCAo (5.2+/-0.6 and 8.4+/-0.5, respectively; P<0.001). T
reatment with MRZ 2/579 also significantly reduced total infarct volume (29
.3+/-11.1 and 83.2+/-16.5 mm(3), respectively; P<0.01), cortical infarct vo
lume (24.8+/-11.2 and 70.0+/-18.0 mm(3), respectively; P<0.04) and subcorti
cal infarction (21.2+/-4.1 and 49.6+/-4.5 mm(3) respectively; P<0.0002). Br
ain swelling was also markedly reduced compared with vehicle-treated rats (
4.7+/-1.3 and 10.8+/-2.1%, respectively; P<0.02). These results demonstrate
that treatment with MRZ 2/579, when administered promptly after reperfusio
n, confers neuroprotective effects on infarct volume, brain swelling, and n
eurological score compared to the vehicle group. (C) 2000 Elsevier Science
B.V. All rights reserved.